Grace Therapeutics Reports 2026 Annual Meeting Voting Results

What Happened
Grace Therapeutics, Inc. (GRCE) filed an 8-K reporting the results of its Annual Meeting of Stockholders held September 17, 2026. Stockholders representing 9,973,325 shares (61.28% of 16,274,026 issued and outstanding shares as of the July 20, 2026 record date) were present or represented by proxy. All five director nominees were elected and stockholders approved the advisory say-on-pay vote and ratified KPMG LLP as the company’s independent registered public accounting firm.

Key Details

• Meeting attendance: 9,973,325 shares present/represented (61.28% of 16,274,026 outstanding).
• Director elections (votes For / Withheld / Broker non-votes):
  • Vimal Kavuru: 6,005,964 / 35,000 / 3,932,361
  • A. Brian Davis: 6,015,486 / 25,478 / 3,932,361
  • Prashant Kohli: 6,010,703 / 30,261 / 3,932,361
  • S. George Kottayil: 6,012,379 / 28,585 / 3,932,361
  • Edward Neugeboren: 6,015,788 / 25,176 / 3,932,361
• Advisory vote on executive compensation (say-on-pay): For 5,740,999; Against 222,775; Abstain 77,190; Broker non-votes 3,932,361.
• Ratification of independent auditor: KPMG LLP ratified — For 9,878,292; Against 63,381; Abstain 31,652.
• Advisory vote on frequency of future say-on-pay votes: 1 year received the plurality (5,772,652 votes); the Board will include an annual say-on-pay vote going forward.

Why It Matters
These results confirm the incumbent board’s continuity and shareholder support for management’s compensation practices (advisory), while also giving KPMG formal approval to continue as auditor for the fiscal year ending March 31, 2027. The substantial number of broker non-votes on director and compensation proposals reflects shares held by brokers that did not vote on those matters and may affect vote totals for non-routine items. For investors, the outcomes reduce near-term governance uncertainty by maintaining current leadership and auditor arrangements and committing the company to annual advisory votes on executive pay.